LBA32Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
Tabernero, J, Grothey, A, Van Cutsem, E, Yaeger, R, Wasan, H, Yoshino, T, Desai, J, Ciardiello, F, Loupakis, F, Hong, Y Sang, Steeghs, N, Guren, T K, Arkenau, H-T, García-Alfonso, P, Gollerkeri, A, PiVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz394.021
Date:
October, 2019
Fichier:
PDF, 78 KB
2019
File converter
Plus de résultats de recherche
More benefits 
